🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 21 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 15/02/2013 | 45,64 | 45,98 | 45,35 | 45,61 | -0,11% | 1,38% | 1.139.700 |
| 14/02/2013 | 46,39 | 46,46 | 45,35 | 45,66 | -1,76% | 2,39% | 1.347.800 |
| 13/02/2013 | 46,02 | 46,72 | 45,79 | 46,48 | +1,29% | 2,02% | 1.586.900 |
| 12/02/2013 | 45,81 | 46,20 | 45,50 | 45,89 | +0,42% | 1,53% | 1.394.000 |
| 11/02/2013 | 46,48 | 46,48 | 45,60 | 45,70 | -0,65% | 1,89% | 862.300 |
| 08/02/2013 | 45,84 | 46,37 | 45,70 | 46,00 | +0,77% | 1,46% | 870.900 |
| 07/02/2013 | 46,11 | 46,24 | 44,96 | 45,65 | -0,46% | 2,78% | 1.110.200 |
| 06/02/2013 | 45,29 | 46,15 | 45,29 | 45,86 | +0,57% | 1,90% | 1.227.500 |
| 05/02/2013 | 44,63 | 45,67 | 44,55 | 45,60 | +2,17% | 2,51% | 1.246.100 |
| 04/02/2013 | 44,66 | 45,45 | 44,59 | 44,63 | -1,78% | 1,93% | 1.428.500 |
| 01/02/2013 | 45,05 | 46,00 | 44,78 | 45,44 | +1,47% | 2,71% | 1.799.400 |
| 31/01/2013 | 44,48 | 45,25 | 44,27 | 44,78 | +0,29% | 2,20% | 4.665.200 |
| 30/01/2013 | 46,51 | 46,55 | 43,57 | 44,65 | -3,75% | 6,41% | 3.528.600 |
| 29/01/2013 | 46,11 | 46,66 | 46,03 | 46,39 | +1,02% | 1,37% | 1.915.200 |
| 28/01/2013 | 46,21 | 46,69 | 45,65 | 45,92 | -1,99% | 2,25% | 1.971.100 |
| 25/01/2013 | 47,69 | 47,69 | 46,70 | 46,85 | -0,99% | 2,08% | 1.302.100 |
| 24/01/2013 | 46,63 | 47,75 | 46,50 | 47,32 | +1,76% | 2,68% | 1.598.100 |
| 23/01/2013 | 46,91 | 47,29 | 46,47 | 46,50 | -1,21% | 1,75% | 896.900 |
| 22/01/2013 | 46,21 | 47,12 | 45,69 | 47,07 | +1,64% | 3,09% | 1.575.200 |
| 18/01/2013 | 46,48 | 46,66 | 45,54 | 46,31 | -1,03% | 2,41% | 1.800.300 |
| 17/01/2013 | 46,60 | 47,32 | 46,48 | 46,79 | +0,73% | 1,80% | 1.369.600 |
| 16/01/2013 | 47,08 | 47,36 | 46,34 | 46,45 | -1,34% | 2,17% | 1.482.300 |
| 15/01/2013 | 45,77 | 47,60 | 45,31 | 47,08 | -0,55% | 5,00% | 2.952.400 |
| 14/01/2013 | 47,12 | 47,75 | 46,79 | 47,34 | +0,06% | 2,04% | 2.102.400 |
| 11/01/2013 | 47,04 | 47,42 | 46,31 | 47,31 | +1,09% | 2,36% | 1.695.200 |
| 10/01/2013 | 48,59 | 48,63 | 46,25 | 46,80 | -3,01% | 4,90% | 2.511.400 |
| 09/01/2013 | 48,54 | 48,70 | 47,52 | 48,25 | -0,52% | 2,43% | 1.920.300 |
| 08/01/2013 | 47,44 | 48,57 | 47,07 | 48,50 | +2,56% | 3,16% | 2.282.200 |
| 07/01/2013 | 45,88 | 47,44 | 45,75 | 47,29 | +3,14% | 3,68% | 2.515.300 |
| 04/01/2013 | 45,35 | 46,51 | 45,20 | 45,85 | +1,55% | 2,89% | 2.538.100 |